The aim of this study is to generate local data on the safety of Menactra® in individuals 2 to 55 years of age in the Russian Federation.

Primary Objective:

• To describe the safety profile after 1 dose of Menactra® administered in individuals 2-55 years of age under standard health care practices.

Participants will be enrolled after receipt of one dose of Menactra® during a routine health care visit. They will be monitored for safety throughout the study.

Inclusion Criteria:

• Aged 2 through 55 years on the day of enrollment "2 through 55 years" means from the day of the 2nd birthday to the day before the 56th birthday
• For adults (18-55 years old) Informed consent form has been signed and dated by the participant.
• For minors: Informed consent form has been signed and dated by the parent. In addition, in accordance with the Institution Ethics Committee/Institution Review Board requirements and as appropriate for the age of the participant:
• participants aged 14 to 17 years are required to sign and date the informed consent form,
• participants aged 10 to 13 years are required to sign and date the assent form,
• for participants under 10 years, consent may be asked orally according to participant's age and ability for understanding
• Receipt of one dose of Menactra® on the day of inclusion and prior to enrollment into the study, in routine practice according to the approved local product insert.

Exclusion Criteria:

• Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device, or medical procedure.

Participants aged 2 to 55 years will be enrolled after receipt of one dose of Menactra® during a routine health care visit.

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org